Etesevimab

An anti-Spike (SARS-CoV-2) monoclonal antibody.

Phase of research

Emergency use authorization

How it helps

Antiviral

Drug status

Experimental

1
Supporting references
1
Contradictory references
6
Clinical trials

General information

Etesevimab is a human recombinant monoclonal antibody targeting SARS-CoV-2 Spike protein RBD. It blocks the interaction between viral Spike and the host’s ACE2 receptor and is therefore investigated in COVID-19 treatment (DrugBank).

On February 9, 2021, the FDA issued an Emergency Use Authorization for emergency use of bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab and etesevimab are neutralizing IgG1 monoclonal antibodies that bind to distinct but overlapping epitopes within the receptor binding domain of the spike protein of SARS-CoV-2. They are both
investigational drugs and are not currently approved for any indication.

 


Synonyms

LY3832479; LY-CoV016; JS016


Supporting references

Contradictory references

Link Tested on Impact factor Notes Publication date DB entry date
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016
antibody Spike protein in vitro
in vitro binding assay N/A (new)

Several mutations, including those found in emerging SARS-CoV-2 variants (P.1 or B.1.351.), were shown to facilitate viral escape from the antibody. For some single mutations or some doble mutations present in certain emergent viral strains, viral escape from the antibody in a cocktail with bamlanivimab is possible, as well.

Apr/01/2021 May/02/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04790786 UPMC OPTIMISE-C19 Trial, a COVID-19 Study Recruiting Phase 3 Mar/10/2021 Dec/01/2022
NCT04931238 Tolerability,Safety of JS016 in SARS-CoV-2 (COVID-19) Recruiting Phase 1 Jan/20/2021 Dec/31/2022
NCT04634409 A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness Recruiting Phase 2 Oct/29/2020 Nov/04/2021
NCT04497987 A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff Completed Phase 3 Aug/02/2020 May/20/2021
NCT04427501 A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness Recruiting Phase 2|Phase 3 Jun/17/2020 Jun/24/2022
NCT04441918 Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects Recruiting Phase 1 Jun/05/2020 Dec/11/2020